TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33982187

Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) resistance training [75% of one‐repetition maximum (1RM), 4 sets, 10 reps]
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low-Intensity Blood-Flow Restricted (LIBFR) exercise [20% of 1RM, 4 sets, 30 + 15 + 15 + 15 reps]
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study: 33048656

Group type: EXPERIMENTAL
Intervention: Interactive online educational intervention utilizing avatars depicting distressed individuals
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Post-test only group (not specified)
Number of subjects: 85
Study: 33386831

Group type: EXPERIMENTAL
Intervention: Myoelectrically controlled FES (MeCFES) followed by robotic therapy (MRG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional rehabilitation care (CG)
Number of subjects: 18
Study: 33325251

Group type: EXPERIMENTAL
Intervention: Fruquintinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33542427

Group type: EXPERIMENTAL
Intervention: Individual dose-volume histograms (IDVHs) method for PTV DVH prediction
Number of subjects: 150

Group type: COMPARATOR
Intervention: Distance-to-target histogram and conformal-plan-dose-volume histogram (DTH + CPDVH) method for OAR DVH prediction
Number of subjects: 150
Study: 33693464

Group type: EXPERIMENTAL
Intervention: Iron supplementation (50 mg daily for 90-120 days)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Preintervention period (no iron supplementation)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Postintervention period (after iron supplementation)
Number of subjects: 21
Study: 32657029

Group type: EXPERIMENTAL
Intervention: SP regimen (raltitrexed plus cisplatin)
Number of subjects: 135

Group type: COMPARATOR
Intervention: FP regimen (5-fluorouracil plus cisplatin)
Number of subjects: 135
Study: 36451379

Group type: EXPERIMENTAL
Intervention: Telenursing counseling (3 sessions for 6 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 108
Study: 34811433

Group type: EXPERIMENTAL
Intervention: Bimanual (BM) digit training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Right-hand (RH) training
Number of subjects: 48
Study: 35221680

Group type: EXPERIMENTAL
Intervention: iCST app
Number of subjects: 61

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 61
Study: 32494128

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) training for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 76
Study: 35747928

Group type: EXPERIMENTAL
Intervention: Viral testing (overall and stratified by testing method)
Number of subjects: 46038

Group type: EXPERIMENTAL
Intervention: Molecular testing
Number of subjects: 46038

Group type: EXPERIMENTAL
Intervention: Antigen testing
Number of subjects: 46038

Group type: COMPARATOR
Intervention: Hospital-specific adjusted proportions of testing
Number of subjects: 46038

Group type: COMPARATOR
Intervention: Viral testing practices
Number of subjects: 46038
Study: 34483020

Group type: EXPERIMENTAL
Intervention: SYN023 + Imovax
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: SYN023 + RabAvert
Number of subjects: 164

Group type: COMPARATOR
Intervention: HyperRab + Imovax
Number of subjects: 164

Group type: COMPARATOR
Intervention: HyperRab + RabAvert
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: SYN023
Number of subjects: 164

Group type: COMPARATOR
Intervention: HyperRab
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: SYN023 and HyperRab
Number of subjects: 164
Study: 35171266

Group type: EXPERIMENTAL
Intervention: Group 1 - Mesenteric sparing ileocolic resection (ICR)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Group 2 - Extensive mesenteric ICR
Number of subjects: 138
Study: 34709859

Group type: EXPERIMENTAL
Intervention: Culturally tailored fruit drink countermarketing messages (fruit drink‒only group)
Number of subjects: 1628

Group type: EXPERIMENTAL
Intervention: Countermarketing and water promotion messages combined (combination group)
Number of subjects: 1628

Group type: COMPARATOR
Intervention: Car-seat safety messages (control)
Number of subjects: 1628
Study: 34954069

Group type: EXPERIMENTAL
Intervention: Scopolamine butylbromide given prophylactically for death rattle
Number of subjects: 1097

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1097
Study: 33737346

Group type: EXPERIMENTAL
Intervention: Comprehensive assessment of IRH severity including laboratory biomarkers and clinical features
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current treatment based on CTCAE grading
Number of subjects: 0
Study: 32506858

Group type: EXPERIMENTAL
Intervention: Honey mouthwash 12.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlorhexidine solution 0.2%
Number of subjects: 60
Study: 33274816

Group type: EXPERIMENTAL
Intervention: Physician's recommendation (surgery)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Physician's recommendation (physiotherapy)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Congruent physician's recommendation
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Contrary physician's recommendation
Number of subjects: 201
Study: 32964800

Group type: EXPERIMENTAL
Intervention: NT-proBNP alone
Number of subjects: 5509

Group type: EXPERIMENTAL
Intervention: NT-proBNP added to the base model
Number of subjects: 5509

Group type: COMPARATOR
Intervention: Base model
Number of subjects: 5509
Study: 35688585

Group type: EXPERIMENTAL
Intervention: Cognitive training plus anodal tDCS over left dorsolateral prefrontal cortex for 2 weeks, 20 min sessions at 1.5 mA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive training plus sham stimulation
Number of subjects: 30
Study: 33529708

Group type: EXPERIMENTAL
Intervention: Imprecise group (visual feedback offset 30 to 50 mm from true location)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Precise group (vision not disrupted)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 32512184

Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 46
Study: 35306716

Group type: EXPERIMENTAL
Intervention: I-CoreDIST
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study: 33109949

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 8000
Study: 35088231

Group type: EXPERIMENTAL
Intervention: Nivolumab plus standard chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 34840512

Group type: EXPERIMENTAL
Intervention: Brief Advice and Counselling
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Five-minute Brief Advice
Number of subjects: 351

Group type: COMPARATOR
Intervention: Patient Information Leaflet
Number of subjects: 351
Study: 35076138

Group type: EXPERIMENTAL
Intervention: Intraarticular injections with 20 mg gold microparticles
Number of subjects: 30
Study: 33369870

Group type: EXPERIMENTAL
Intervention: Intratympanic (IT) dexamethasone administered once every other day for 24 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (IV) dexamethasone for 12 days followed by IT dexamethasone once every other day for 12 days
Number of subjects: 0
Study: 35855628

Group type: EXPERIMENTAL
Intervention: EMG‐driven robotic rehabilitation (Hand of Hope®) with neurophysiological rehabilitation, 15 sessions over 3 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neurophysiological rehabilitation (control group)
Number of subjects: 24
Study: 33309460

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU, once daily for four weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 34
Study: 33121204

Group type: EXPERIMENTAL
Intervention: interACTION system (n = 13)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard post-operative outpatient rehabilitation program (n = 12)
Number of subjects: 25
Study: 36457059

Group type: EXPERIMENTAL
Intervention: ceftolozane/tazobactam (3 g [2 g ceftolozane/1 g tazobactam] every 8 h)
Number of subjects: 93

Group type: COMPARATOR
Intervention: meropenem (1 g every 8 h)
Number of subjects: 93
Study: 33463692

Group type: EXPERIMENTAL
Intervention: Genetically determined vitamin D levels
Number of subjects: 600000
Study: 33301887

Group type: EXPERIMENTAL
Intervention: NSE levels at 24 hours
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NSE levels at 48 hours
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NSE levels at 72 hours
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NSE at 48 hours
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: NSE at 72 hours
Number of subjects: 101

Group type: COMPARATOR
Intervention: Temperature management (33°C vs 37°C)
Number of subjects: 101
Study: 32036192

Group type: EXPERIMENTAL
Intervention: Supplemental perinatal contraceptive counselling (intervention group)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Standard Spanish postpartum contraceptive counselling (control group)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Standard clinical practice (control group)
Number of subjects: 975
Study: 35963558

Group type: EXPERIMENTAL
Intervention: Combined treatment (d-methylphenidate and guanfacine)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: d-methylphenidate
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: guanfacine
Number of subjects: 172
Study: 32965476

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual antiplatelet therapy) for 3 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: Aspirin plus placebo (single antiplatelet therapy) for 3 months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Clopidogrel group at 6 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo group at 6 months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Clopidogrel group at 12 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo group at 12 months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall severity of migraine attacks
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Overall incidence of migraine attacks after 3 months
Number of subjects: 171
Study: 32484877

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vegetable protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Animal protein
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All protein types (whey, vegetable, animal)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: VLCKDs (all types)
Number of subjects: 48
Study: 33801537

Group type: EXPERIMENTAL
Intervention: Mobile mental health apps based on cognitive behavior theory, stress theory, and ecological instant intervention theory (including breathing training, meditation, and music therapy)
Number of subjects: 1205
Study: 33017804

Group type: EXPERIMENTAL
Intervention: 4-km cycling time trial at 08:30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4-km cycling time trial at 11:30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4-km cycling time trial at 14:30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4-km cycling time trial at 17:30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 4-km cycling time trial at 20:30
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Preexercise tympanic temperature at 14:30 and 17:30
Number of subjects: 19
Study: 34779103

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg daily
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 32823324

Group type: EXPERIMENTAL
Intervention: Closed-suction drains (MD)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No closed-suction drains (OD)
Number of subjects: 53
Study: 32456955

Group type: EXPERIMENTAL
Intervention: 3D model‐assisted surgery
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 37
Study: 32649395

Group type: EXPERIMENTAL
Intervention: Active group music therapy program (3 months, twice per week, 60 minutes per session)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Daily activities (comparison group)
Number of subjects: 146
Study: 36775504

Group type: EXPERIMENTAL
Intervention: Superficial dry needling (SDN)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Deep dry needling (DDN)
Number of subjects: 47
Study: 34124927

Group type: EXPERIMENTAL
Intervention: Standard clinic-based cognitive behavioral therapy (S-CBT)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Minimal therapist contact cognitive behavioral therapy (MC-CBT)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Education/Support (EDU)
Number of subjects: 436
Study: 32949063

Group type: EXPERIMENTAL
Intervention: HFrecEF (cases)
Number of subjects: 136

Group type: COMPARATOR
Intervention: HFrEF non-recovered (controls)
Number of subjects: 136
Study: 36495477

Group type: EXPERIMENTAL
Intervention: Mandated case review of high-risk patients prescribed opioids
Number of subjects: 28251

Group type: EXPERIMENTAL
Intervention: Patients who received an opioid prescription prior to but not after OUD diagnosis
Number of subjects: 28251

Group type: COMPARATOR
Intervention: Control patients (not specified in detail)
Number of subjects: 28251
Study: 34008076

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 1
Study: 35780607

Group type: EXPERIMENTAL
Intervention: Deep learning-based synthetic CT (sCT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional CT
Number of subjects: 25
Study: 33525270

Group type: EXPERIMENTAL
Intervention: 0.3g/Kg of a glucose preparation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sugar fondant candies
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fruit juice
Number of subjects: 21
Study: 34688473

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 118
Study: 32615837

Group type: EXPERIMENTAL
Intervention: ‘ward’ vaginal tablet containing 200 mg of dried extract applied vaginally for 7 consecutive nights
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo (corn starch and lactose) applied vaginally for 7 consecutive nights
Number of subjects: 92
Study: 34955699

Group type: EXPERIMENTAL
Intervention: Female investigator
Number of subjects: 40

Group type: COMPARATOR
Intervention: Male investigator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: First series of stimulation
Number of subjects: 40
Study: 34304030

Group type: EXPERIMENTAL
Intervention: COVID-19 safety protocols for conducting the ESSENCE trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for supervisors, travellers, training/recruitment venue safety procedures, individual safety procedures
Number of subjects: 0
Study: 33422263

Group type: EXPERIMENTAL
Intervention: Continuation of renin–angiotensin system inhibitors
Number of subjects: 152

Group type: COMPARATOR
Intervention: Discontinuation of renin–angiotensin system inhibitors
Number of subjects: 152
Study: 34628697

Group type: EXPERIMENTAL
Intervention: Intensive care and education with serial consultations with HF specialist and dietician during the first 2-3 weeks
Number of subjects: 482

Group type: COMPARATOR
Intervention: Standard post-discharge care according to guidelines
Number of subjects: 482
Study: 33639897

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 33031764

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (400 mg and 100 mg, respectively) by mouth for 10 days or until discharge
Number of subjects: 5040

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5040

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 5040

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir (among patients not on invasive mechanical ventilation at baseline)
Number of subjects: 5040

Group type: COMPARATOR
Intervention: Usual care (among patients not on invasive mechanical ventilation at baseline)
Number of subjects: 5040
Study: 35057571

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum CJLP243
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33082286

Group type: EXPERIMENTAL
Intervention: 60 mL 0.375% ropivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: 60 mL isotonic saline (placebo)
Number of subjects: 70
Study: 613168068

Group type: EXPERIMENTAL
Intervention: Nicotinamide (300 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (300 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Purified water (Control)
Number of subjects: 30
Study: 34953155

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/day for 28 days
Number of subjects: 245

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 245
Study: 34311749

Group type: EXPERIMENTAL
Intervention: Vegetables only for 28 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fruit and vegetables for 28 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study: 32198149

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Serial radiographic measurements
Number of subjects: 188
Study: 32407532

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 469

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 469
Study: 33027765

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Static Stretching (SS)
Number of subjects: 40
Study: 35447502

Group type: EXPERIMENTAL
Intervention: Intravenous calcium chloride (1 gram)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline placebo control
Number of subjects: 40
Study: 33834863

Group type: EXPERIMENTAL
Intervention: Fufang E’jiao Syrup (FFEJS), 20 ml, 3 times a day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, 20 ml, 3 times a day for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fufang E’jiao Syrup (FFEJS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32681734

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance training program (n = 15)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-training group (n = 18)
Number of subjects: 33
Study: 35750564

Group type: EXPERIMENTAL
Intervention: Self-irrigation with tap water using a syringe three times a day, starting seven days after tooth extraction
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Self-irrigation with tap water
Number of subjects: 155
Study: 34179759

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34999739

Group type: EXPERIMENTAL
Intervention: Whole grain wheat products (semolina)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Whole grain wheat products (cracked wheat)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Whole wheat flour porridge
Number of subjects: 16
Study: 33823195

Group type: EXPERIMENTAL
Intervention: Cigarette smoke
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biomass smoke
Number of subjects: 0
Study: 36463498

Group type: EXPERIMENTAL
Intervention: Live music during haemodialysis (30 minutes once a week for 6 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Live music during haemodialysis
Number of subjects: 24
Study: 34295831

Group type: EXPERIMENTAL
Intervention: Adjunctive probiotic group (Lacticaseibacillus rhamnosus GR‐1 and Limosilactobacillus reuteri RC‐14 orally for 30 days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Metronidazole group (metronidazole vaginal suppositories for 7 days)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Adjunctive probiotic group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Metronidazole group
Number of subjects: 126
Study: 34655389

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Support/Education (active control intervention)
Number of subjects: 67
Study: 32273381

Group type: COMPARATOR
Intervention: Standard USAF SAPP
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: USAF SAPP with MI enhancement
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups (Standard USAF SAPP and USAF SAPP with MI enhancement)
Number of subjects: 51
Study: 36050448

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T)
Number of subjects: 2821

Group type: EXPERIMENTAL
Intervention: Trastuzumab (T) + Lapatinib (L)
Number of subjects: 2821

Group type: COMPARATOR
Intervention: Lapatinib (L)
Number of subjects: 2821
Study: 33160896

Group type: EXPERIMENTAL
Intervention: Mummy Buddy Program (peer support intervention)
Number of subjects: 47
Study: 35176755

Group type: EXPERIMENTAL
Intervention: Tamoxifen (Arm A, TAMOX/VOR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vorinostat (Arm B, VOR)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tamoxifen and Vorinostat
Number of subjects: 31
Study: 34487958

Group type: EXPERIMENTAL
Intervention: Extremely randomized neural networks
Number of subjects: 0

Group type: COMPARATOR
Intervention: State-of-the-art methods (MC dropout and bootstrap procedures)
Number of subjects: 0
Study: 35238305

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg/day for 7 days)
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497